Studies showing putative involvement of Negr1 in psychiatric disorders
| Literature | Disease targeted | Subject | Main findings |
|---|---|---|---|
| Singh et al. 2019 [23] | General psychiatric disorders | - Enlarged ventricle. - Decreased number of parvalbumin-positive inhibitory interneurons in hippocampus. - Hyperactivity in social interaction. - Impaired social dominance behavior. |
|
| Maccarrone et al. 2013 [55] | Major depressive disorder (MDD), Bipolar disorder, Schizophrenia (SCZ) | Human | - Identification of association of Negr1 as a MDD-specific protein biosignature in cerebrospinal fluid of MDD patient. |
| Szczurkowska et al. 2018 [27] | Autism spectrum disorder (ASD) | - Impaired ultrasonic vocalization. - Increased latency to respond to thermal stimuli. - Less sniffing, More grooming. |
|
| Ni et al. 2018 [70] | Major depressive disorder (MDD), Alzheimer’s disease (AD) | Human, mouse | - Identification of Negr1 as a common variants in the MDD GWAS loci with AD. - Reduced mRNA expression in the entorhinal cortex and temporal cortex in human AD patient. - Significant correlation of Negr1 mRNA expression level with both amyloid-β (Aβ) and tau (Tau) burden in AD mouse model. |
| Karis et al. 2018 [71] | Schizophrenia (SCZ) | Human | - Increased Negr1 transcript level in dorsolateral prefrontal cortex in SCZ patient. |
| Noh et al. 2019 [60] | Major depressive disorder (MDD) | - Increased anxiety- and depressive-like behavior. - Decreased hippocampal neurogenesis. - Reduced Lipocalin-2 (Lcn2) expression in hippocampus. - Impaired LTP and mEPSC in hippocampal dentate gyrus. |
|
| Amare et al. 2018 [56] | Major depressive disorder (MDD) | Human | - Identification of association of Negr1 in SSRI treatment response. |